Showing 4 results for Alopecia Areata
Amir Hooshang Ehsani, Mahbobeh Sadat Hosseyni, Amir Reza Hanifnia,
Volume 3, Issue 1 (3-2012)
Abstract
Background and Aim: Alopecia areata is a non-scarring hair disorder. Trace elements imbalance (like zinc) has been reported as its triggering factor. In this study we compared serum zinc level in alopecia areata patients with normal values.Methods: Twenty-three female and 19 male patients with alopecia areata were recruited and their serum zinc levels were assessed using absorption spectrometery. Chi squared, t and ANOVA tests were used for statistical analysis.
Results: Sixteen patients with more extensive and prolonged disease, had serum zinc level lower than normal (70 µg/dL). The means of serum zinc levels in patients and normal population were 81.88 µg/dL and 83.5 µg/dL, respectively. This difference was not significant (P=0.668). The means of serum zinc level in different types of alopecia areata were not significantly different (P>0.05). There was an association between serum zinc level and disease duration (P=0.022).
Conclusion: Patients with more severe forms of alopecia areata had lower serum zinc level than other forms of the disease.
Nafiseh Esmaeili, Md, Zahra Halaji, Md, Amirhooshang Ehsani, Md, Mahboubeh Eghbalian, Md, Abbas Karimi,
Volume 4, Issue 2 (6-2013)
Abstract
Background and Aim: Alopecia Areata is a chronic inflammatory disease which involves hair follicles. The aim of this study was to assess the efficacy of oral sulfasalazine in the treatment of recalcitrant alopecia areata.
Methods: Patients with refractory alopecia areata who were eligible for the study, after providing informed consent were treated with oral sulfasalazine for 6 months. After completion of treatment, regrowth of vellus and terminal hairs were determined based on clinical examination and comparing the new photographs with the baseline ones.
Results: Sixteen patients were enrolled in the present study but only 5 patients completed it. No response was seen in 3 patients. After 4 months, 55-60% response to treatment was observed in 1 patient, but the disease relapsed at the end of fourth month. In 1 patient, 15% hair regrowth was observed but treatment was discontinued after the second month due to side effects. Side effects were observed in 2 patients.
Conclusion: Since only refractory alopecia areata patients had been enrolled to the study, the results could not be generalized to all patients with alopecia areata. Therapeutic response in the patients with alopecia areata is disappointing and any poor treatment response or failure of treatment in refractory cases of the disease cannot rule out the efficacy of the drug in the milder forms of the alopecia areata.
Majid Banimohammad, Mahdi Forghani Ramandi, Hamidreza Pazoki Toroudi,
Volume 12, Issue 2 (8-2021)
Abstract
Alopecia areata (AA) is a sudden non-scarring hair loss that can be seen in any hairy area in the form of round or oval patches. It is an autoimmune disorder with an immunological response against hair follicles that is caused by genetic and environmental factors. The prevalence of AA is about 0.1% to 0.2% worldwide. Depending on the severity of the disease and sites of involvement, it can be divided into: Alopecia with Patchy pattern, alopecia reticularis, alopecia totalis, alopecia universalis, alopecia ophiasis, alopecia sisiapho, diffuse type and perinevoid alopecia areata. There are various treatment options for AA, but once terminated, they have a high recurrence rate. AA is known for the infiltration of T lymphocytes around the hair follicle bulb, and corticosteroids are its main treatment. Another treatment is topical immunotherapy, the most important of which is Diphenylcyclopropenone (DPCP). It is used in cases that have more than 50% hair loss or are resistant to treatment. The exact DPCP mechanism of action is not well understood, but it may have some kind of antigenic competition and reduce the production of anti-hair follicle antibodies. It can alter the immune response in the skin and alter the ratio of CD4 to CD8 cells around the hair follicle in a way that enhances healing of the disease. It is stated that the rate of hair regrowth in DPCP treatment is about 50% on average. In this article, we review the latest findings of about AA and discuss its therapeutic aspects, especially with DPCP.
Ilshan Lotfi, Seyedsaeed Tamehrizadeh, Mohammadhassan Javanbakht, Maryam Ghiasi, Mahshid-Ol-Sadat Ansari,
Volume 13, Issue 3 (11-2022)
Abstract
Background and Aim: Alopecia areata is an autoimmune disease of hair follicle. Osteopontin is an early T lymphocyte activator that may play a role in some immunological diseases. The aim of this study was to evaluate the serum level of osteopontin in patients with alopecia areata and compare it with the level in normal subjects.
Methods: 54 patients with alopecia areata who presented to the Razi Hospital in Tehran in 2017 and 2018 were enrolled. Half of the patients had severe disease and half of them had mild disease. Also, 52 healthy subjects were selected as control group (age and sex matched). The severity of disease was determined using SALT Score. Serum osteopontin levels were measured by ELISA method.
Results: The results showed that serum osteopontin levels were significantly higher in patients with alopecia areata than healthy subjects. There was no significant relationship between osteopontin level and SALT score or duration of the disease.
Conclusion: The level of osteopontin is higher in AA patients than normal subjects but it does not correlate with the severity of disease.
